NCT03329950 - A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

September 13, 2022

Study Completion Date

September 13, 2022

Conditions

MelanomaNon-small Cell Lung CancerBreast CancerGastric CancerRenal Cell CarcinomaOvarian CancerCholangiocarcinomaBladder Urothelial CarcinomaPancreatic AdenocarcinomaColorectal CancerEsophageal CancerHepatic CancerHead and Neck CancerPrimary Peritoneal CancerFallopian Tube CancerOther Solid TumorsDiffuse Large B-cell Lymphoma (DLBCL)Mantle Cell LymphomaIndolent B-cell LymphomasNon-Hodgkin LymphomaFollicular LymphomaLymphoplasmacytic LymphomaWaldenstrom's DiseaseMarginal Zone LymphomaMucosa Associated Lymphoid TissueSmall Lymphocytic Leukemia

Interventions

DRUG

CDX-1140

CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.

DRUG

CDX-301

CDX-301 will be injected once a day for five days before Cycles 1 and 2.

DRUG

pembrolizumab

pembrolizumab will be administered every 3 weeks.

DRUG

Chemotherapy

Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.

Trial Locations (11)

10029

Icahn School of Medicine at Mount Sinai, New York

10065

Memorial Sloan Kettering Cancer Center, New York

19104

Abramson Cancer Center at the University of Pennsylvania, Philadelphia

30342

Northside Hospital, Inc., Atlanta

30912

Georgia Cancer Center at Augusta University, Augusta

44718

Gabrail Cancer Center Research LLC, Canton

68130

Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha

77030

Houston Methodist, Houston

85258

HonorHealth Research Insititute, Scottsdale

97213

Providence Portland Medical Center, Portland

02903

Rhode Island Hospital (RIH) The Miriam Hospital (TMH), Providence